Wave Life Sciences (WVE) Set to Announce Earnings on Thursday

Wave Life Sciences (NASDAQ:WVE) is set to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Wave Life Sciences (NASDAQ:WVE) last issued its earnings results on Wednesday, March 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. The firm had revenue of $29.06 million during the quarter, compared to analyst estimates of $23.30 million. During the same quarter in the prior year, the business earned ($0.47) earnings per share. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Trading Up 0.7 %

Shares of NASDAQ:WVE opened at $5.79 on Wednesday. Wave Life Sciences has a 52-week low of $3.15 and a 52-week high of $7.67. The business’s 50 day simple moving average is $5.72 and its two-hundred day simple moving average is $5.18.

Wall Street Analyst Weigh In

WVE has been the subject of a number of recent research reports. StockNews.com lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 18th. Royal Bank of Canada reiterated a “sector perform” rating and set a $5.00 price target on shares of Wave Life Sciences in a research note on Thursday, March 7th. HC Wainwright boosted their price objective on Wave Life Sciences from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. Finally, Truist Financial restated a “buy” rating and issued a $17.00 target price on shares of Wave Life Sciences in a report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Wave Life Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $10.14.

Insider Transactions at Wave Life Sciences

In other news, CFO Kyle Moran sold 15,630 shares of Wave Life Sciences stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $6.17, for a total value of $96,437.10. Following the completion of the transaction, the chief financial officer now owns 33,921 shares in the company, valued at $209,292.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 31.10% of the stock is owned by corporate insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.